The Evolving Landscape of PD-1/PD-L1 Pathway in Head and Neck Cancer

Qiao, Xinwei; Jiang, Jian; Pang, Xin; Huang, Mengyuan; Tang, Ya‐Jie; Liang, Xin‐hua; Tang, Yaling

doi:10.3389/fimmu.2020.01721

Cited by 69 publications

(72 citation statements)

References 118 publications

(144 reference statements)

Supporting

Mentioning

Contrasting

Order By: Relevance

“…Reduction in dose of radiotherapy, use of cetuximab ( Marur et al, 2017 ) instead of cisplatin for chemoradiation, and transoral robotic surgery (TORS) are a few efforts to mention that are specifically directed to HPV-positive HNC. Considering HPV-positive tumors to be immunologically active, in recent past, attempts have been made to design PD1-PDL1 immunotherapeutic strategies ( Qiao et al, 2020 ). New cancer immune-prevention treatments include FDA-approved inhibitory antibodies such as pembrolizumab (anti-PD1 mAb), nivolumab (anti-PD1), and ipilimumab (anti–CTLA-4 mAb) ( Bauman and Ferris, 2014 ; Ferris et al, 2018 ; Mehra et al, 2018 ; Havel et al, 2019 ); co-stimulation and co-inhibition pathways ( Kuss et al, 2003 ; Tsukishiro et al, 2003 ; Baruah et al, 2012 ; Pardoll, 2012 ); and check-point blockade therapy ( Davis et al, 2016 ; Muzaffar et al, 2021 ).…”

Section: Head and Neck Cancer Spectrummentioning

confidence: 99%

Phytochemicals as Potential Chemopreventive and Chemotherapeutic Agents for Emerging Human Papillomavirus–Driven Head and Neck Cancer: Current Evidence and Future Prospects

et al. 2021

View full text Add to dashboard Cite

Head and neck cancer (HNC) usually arises from squamous cells of the upper aerodigestive tract that line the mucosal surface in the head and neck region. In India, HNC is common in males, and it is the sixth most common cancer globally. Conventionally, HNC attributes to the use of alcohol or chewing tobacco. Over the past four decades, portions of human papillomavirus (HPV)-positive HNC are increasing at an alarming rate. Identification based on the etiological factors and molecular signatures demonstrates that these neoplastic lesions belong to a distinct category that differs in pathological characteristics and therapeutic response. Slow development in HNC therapeutics has resulted in a low 5-year survival rate in the last two decades. Interestingly, HPV-positive HNC has shown better outcomes following conservative treatments and immunotherapies. This raises demand to have a pre-therapy assessment of HPV status to decide the treatment strategy. Moreover, there is no HPV-specific treatment for HPV-positive HNC patients. Accumulating evidence suggests that phytochemicals are promising leads against HNC and show potential as adjuvants to chemoradiotherapy in HNC. However, only a few of these phytochemicals target HPV. The aim of the present article was to collate data on various leading phytochemicals that have shown promising results in the prevention and treatment of HNC in general and HPV-driven HNC. The review explores the possibility of using these leads against HPV-positive tumors as some of the signaling pathways are common. The review also addresses various challenges in the field that prevent their use in clinical settings.

show abstract

Section: Head and Neck Cancer Spectrummentioning

confidence: 99%

Phytochemicals as Potential Chemopreventive and Chemotherapeutic Agents for Emerging Human Papillomavirus–Driven Head and Neck Cancer: Current Evidence and Future Prospects

et al. 2021

View full text Add to dashboard Cite

show abstract

“…expression and further research is warranted in this direction to assess their potential functions and roles [9]. Although these results appear promising, genomic barriers such as tumor inter and intra heterogeneity still remain in front of PD-L1 being used as an effective biomarker in this neoplasm.…”

Section: A B C Dmentioning

confidence: 99%

Pd-L1 Testing and Immunotherapy Selection – Early Laboratory Experience and Its Potential Role in Head and Neck Cancer Management

2021

View full text Add to dashboard Cite

Anti-programmed cell death protein-1 (PD-1) therapy has been relatively recently approved in a defined context by NICE in adults in the management of recurrent and metastatic head and neck squamous cell carcinomas (HNSCC). In this context, companion diagnostic programmed cell death ligand-1 (PD-L1) testing, previously established at our center for lung and bladder tumors, was undertaken in a few head and neck cancer cases. The scope of this study was to audit the relevant PD-L1 data and integrate the findings in our current clinical practice, with a view to promote improved routine laboratory biomarkers in HNSCC. Histopathology reports documenting tumor type, PD-L1 result and type of clone/assay were included in this study. Over a 5-year period, PD-L1 testing was undertaken in 199 cancer cases, including 3 with head and neck squamous carcinoma with low focal positive staining. Immunotherapy treatment in HNSCC demonstrates a discreet but still significant improvement in the overall survival of PD-L1 positive subjects.

show abstract

“…First, there is growing evidence that HNSCCs are extremely immunosuppressive malignancy owing to disruption of T-cells signaling, induction of immune tolerance, and immune evasion [ 5 , 6 ]. Second, infiltration of immunosuppressive cells, including regulatory T (Treg) cells, as well as an increase in the expression of co-inhibitory receptors on T-cells, including programmed cell death protein 1 (PD-1) and cytotoxic T-lymphocyte-associated protein 4 (CTLA-4) in the HNSCCs microenvironment are attractive targets for immunotherapy [ 7 , 8 ]. Third, the HPVs-associated sub-set of HNSCC has a distinct immune cell profile in the tumor microenvironment (TME), providing a suitable antigenic target [ 9 ].…”

Section: Introductionmentioning

confidence: 99%

A review on the advances and challenges of immunotherapy for head and neck cancer

et al. 2021

View full text Add to dashboard Cite

Head and neck cancer (HNC), which includes lip and oral cavity, larynx, nasopharynx, oropharynx, and hypopharynx malignancies, is one of the most common cancers worldwide. Due to the interaction of tumor cells with immune cells in the tumor microenvironment, immunotherapy of HNCs, along with traditional treatments such as chemotherapy, radiotherapy, and surgery, has attracted much attention. Four main immunotherapy strategies in HNCs have been developed, including oncolytic viruses, monoclonal antibodies, chimeric antigen receptor T cells (CAR-T cells), and therapeutic vaccines. Oncorine (H101), an approved oncolytic adenovirus in China, is the pioneer of immunotherapy for the treatment of HNCs. Pembrolizumab and nivolumab are mAbs against PD-L1 that have been approved for recurrent and metastatic HNC patients. To date, several clinical trials using immunotherapy agents and their combination are under investigation. In this review, we summarize current the interaction of tumor cells with immune cells in the tumor microenvironment of HNCs, the main strategies that have been applied for immunotherapy of HNCs, obstacles that hinder the success of immunotherapies in patients with HNCs, as well as solutions for overcoming the challenges to enhance the response of HNCs to immunotherapies.

show abstract

The Evolving Landscape of PD-1/PD-L1 Pathway in Head and Neck Cancer

Cited by 69 publications

References 118 publications

Phytochemicals as Potential Chemopreventive and Chemotherapeutic Agents for Emerging Human Papillomavirus–Driven Head and Neck Cancer: Current Evidence and Future Prospects

Phytochemicals as Potential Chemopreventive and Chemotherapeutic Agents for Emerging Human Papillomavirus–Driven Head and Neck Cancer: Current Evidence and Future Prospects

Pd-L1 Testing and Immunotherapy Selection – Early Laboratory Experience and Its Potential Role in Head and Neck Cancer Management

A review on the advances and challenges of immunotherapy for head and neck cancer

Contact Info

Product

Resources

About